Why Dyne Therapeutics Stock Was Blasting Higher Today
Key Points
Its No. 1 drug candidate did well in a clinical trial.
It met both its primary and secondary endpoints.
- 10 stocks we like better than Dyne Therapeutics ›
Dyne Therapeutics (NASDAQ: DYN) was hardly having a bad case of the Mondays. Shares of the clinical-stage biotech were racing more than 9% higher in mid-session action, as the company delivered rather encouraging news about one of its investigational drugs.
DMD drug's solid results
Before market open, Dyne announced that its zeleciment rostudirsen -- a treatment targeting the genetic disorder Duchenne muscular dystrophy (DMD) -- had achieved its primary endpoint in a phase 1/2 clinical trial involving 86 patients. It also met its secondary endpoints.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
According to the healthcare company, the drug demonstrated a statistically significant increase in the production of dystrophin, a structural protein that protects muscles. The treatment also performed efficaciously when compared to a placebo.
In the press release touting the readout, Dyne said that it is now on pace to submit zeleciment rostudirsen for accelerated approval by the U.S. Food and Drug Administration (FDA) in the second quarter of next year.
Developing well so far
This is indisputably excellent news for Dyne and its leading drug candidate. I should caution here that there is still plenty of work to be done in the development of zeleciment rostudirsen, and FDA approval is not guaranteed. That said, the medicine is well on track to become a significant product in the DMD space in the proximate future.
Should you invest $1,000 in Dyne Therapeutics right now?
Before you buy stock in Dyne Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Dyne Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $540,587!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,118,210!*
Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of December 8, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
